NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Graft-versus-Host Disease

Interventions: ruxolitinib

Countries: South Korea

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients

Eligibility overview

Sex: ALL

Age: 12 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label
2. Patients who are willing to provide written informed consent prior to study enrollment

Exclusion Criteria:

1. Patients under 12 years old
2. Patients with contraindication according to locally approved label of Jakavi®
3. Patients who receive or are going to receive any investigational medicine during the observation period.

Locations (14)

Daegu, Dalseo gu, South Korea
Wŏnju, Gangwon-do, South Korea
Uijeongbu-si, Gyeonggi-do, South Korea
Jinju, Gyeongsangnam-do, South Korea
Gyeonggi-do, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Seoul, South Korea
Busan, South Korea
Busan, South Korea
Busan, South Korea
Jeollanam, South Korea
Seoul, South Korea
Seoul, South Korea
Taegu, South Korea